Schreiber, Liesa-Marie
Urbiola, Carles
Das, Krishna
Spiesschaert, Bart
Kimpel, Janine
Heinemann, Fabian
Stierstorfer, Birgit
Müller, Philipp
Petersson, Monika
Erlmann, Patrik
von Laer, Dorothee
Wollmann, Guido
Funding for this research was provided by:
Christian Doppler Forschungsgesellschaft
Article History
Received: 30 January 2019
Revised: 30 July 2019
Accepted: 19 August 2019
First Online: 18 September 2019
Competing interests
: D.v.L. is inventor on a patent related to VSV-GP. D.v.L. and G.W. serve as scientific advisors for Boehringer Ingelheim GmbH. F.H., B.St. and P.M. are employees of Boehringer Ingelheim Pharma GmbH. B.Sp., M.P. and P.E. are employees of ViraTherapeutics GmbH. The remaining authors declare no competing interests.
: The studies were performed in compliance with the Austrian experimentation law. Animal trial permission was granted by the national authorities (BMWFW-66.011/0012-WF/V/3b/2016 and BMWFW-66.011/0041-WF/V/3b/2016).
: This study was supported by a grant from the Christian Doppler Research Association (L.M.S., C.U., B.S., G.W.).
: All pertinent data to support this study are included in the manuscript and supplementary files. Further data supporting the findings are available upon request.